Stevia Rebaudiana Bertoni on Levels of GCF Glucose and Bio-markers in Diabetics.
Launched by SVS INSTITUTE OF DENTAL SCIENCES · May 5, 2020
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
Stevia is considered as a novel molecule, because it is 100% natural and non caloric sweetener, with more sweetness than sucrose, without any adverse effects. It also demonstrates multiple benefits like anti-plaque effect, anti-diabetic effect, anti-periodontophatics properties, anti-hypertensive properties, anti-cariogenic properties etc. There are many studies conducted on stevia in humans, which justifies my study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects that will be included in the study are in the age group ranging from 20-70 years -with established diabetes and under medication to maintain normal glycemic state i.e;Hb1Ac \< 7%.
- • Oral findings including the presence of minimum of 16 natural teeth with minimum of 4 nonadjacent sites showing pocket depths≥ 5 mm.
- Exclusion Criteria:
- • Subjects will be excluded from the study if they are using
- • any type of mouth-rinses or if they had underwent any periodontal therapy within the 3-months of the study or
- • if they were under antibiotics within the 3-months of the study.
About Svs Institute Of Dental Sciences
SVS Institute of Dental Sciences is a leading clinical research organization dedicated to advancing dental health through innovative research and development. With a commitment to excellence in clinical trials, the institute collaborates with dental professionals, researchers, and healthcare institutions to explore new treatments and technologies in dentistry. Its state-of-the-art facilities and experienced team ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment of scientific integrity. By prioritizing patient safety and outcomes, SVS Institute of Dental Sciences aims to contribute significantly to the field of dental medicine and improve overall oral health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hyderabad, Telangana, India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials